-

09:09:46 PM

ADMP Stock News

ADMP - Adamis Pharmaceuticals Corp

11/14/22 4:10 PM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various

RHEA-AI

neutral

11/07/22 4:05 PM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor

RHEA-AI

neutral

10/03/22 4:30 PM

Nasdaq : ADMP

Adamis Announces Review of Strategic Alternatives

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory

RHEA-AI

neutral

09/21/22 7:30 AM

Nasdaq : ADMP

clinical trialcovid-19

Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Independent Data Safety Monitoring Board recommends halting the trial SAN DIEGO, Sept. 21, 2022 (GLOBE

RHEA-AI

neutral

09/12/22 4:05 PM

Nasdaq : ADMP

clinical trialcovid-19

Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced

RHEA-AI

neutral

08/12/22 5:00 PM

Nasdaq : ADMP

Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled. At

RHEA-AI

neutral

08/10/22 4:02 PM

Nasdaq : ADMP

earnings

Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various

RHEA-AI

neutral

07/29/22 8:00 AM

Nasdaq : ADMP

Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting

Adamis Pharmaceuticals Corporation

RHEA-AI

neutral

07/29/22 7:30 AM

Nasdaq : ADMP

clinical trialcovid-19

Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.

RHEA-AI

neutral

07/21/22 7:30 AM

Nasdaq : ADMP

Adamis Pharmaceuticals Issues Letter to Stockholders

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

ADMP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.adamispharmaceuticals.com
CeoDennis Carlo
Security nameAdamis Pharmaceuticals Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees130
Tags
- Health Technology
- Pharmaceuticals: Other
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address11682 El Camino Real Ste 300
StateCalifornia
CitySan Diego
Zip92130
CountryUS
Phone18589972400

About Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements